Lipocine Reports LPCN 2401 Rapidly Improves Body Composition and Liver <a href="https://laohu8.com/S/HIT">Health in</a> Obese Men
Lipocine Inc. has announced the presentation of clinical data for LPCN 2401 at the ObesityWeek® annual meeting in Atlanta, Georgia, held from November 4 to 7, 2025. The results, featured in a poster session, include 20-week data from a completed Phase 2 trial evaluating LPCN 2401 in men with obesity. The study found that treatment with LPCN 2401, both alone and in combination with vitamin E, resulted in rapid improvements in body composition, including increased lean mass and reduced fat mass and fat-to-lean mass ratio, compared to placebo. Additionally, significant reductions in liver fat content and liver injury markers were observed after 12 weeks of treatment and maintained through 36 weeks. LPCN 2401 was reported to be well tolerated, with no concerning safety signals identified through 72 weeks of exposure. The clinical results were presented during the ObesityWeek® meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lipocine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-020677), on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.